Scarica l'app Stockscreener
61.23
1.76%
-1.10
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$62.33
Aprire:
$62.01
Volume 24 ore:
985.43K
Relative Volume:
0.65
Capitalizzazione di mercato:
$8.51B
Reddito:
$105.82M
Utile/perdita netta:
$-829.61M
Rapporto P/E:
-8.948
EPS:
-6.8429
Flusso di cassa netto:
$-548.92M
1 W Prestazione:
-1.16%
1M Prestazione:
-6.96%
6M Prestazione:
-6.49%
1 anno Prestazione:
+6.49%
Intervallo 1D:
$60.89
$62.44
Intervallo di 1 settimana:
$60.89
$64.78
Portata 52W:
$54.30
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
Nome
Cytokinetics Inc
Settore
Industria
Telefono
(650) 624-3000
Indirizzo
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
61.23 | 8.51B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-29 | Aggiornamento | UBS | Neutral → Buy |
| 2026-05-19 | Iniziato | Citigroup | Buy |
| 2026-04-10 | Iniziato | Wells Fargo | Overweight |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-12-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-07-30 | Ripresa | Raymond James | Mkt Perform |
| 2025-04-24 | Iniziato | Barclays | Overweight |
| 2025-02-07 | Iniziato | Citigroup | Buy |
| 2025-01-22 | Iniziato | Stifel | Buy |
| 2024-11-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-13 | Downgrade | Goldman | Buy → Neutral |
| 2024-01-24 | Downgrade | UBS | Buy → Neutral |
| 2024-01-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Iniziato | Goldman | Buy |
| 2023-11-07 | Iniziato | B. Riley Securities | Buy |
| 2023-08-15 | Iniziato | SVB Securities | Outperform |
| 2023-02-17 | Iniziato | BofA Securities | Neutral |
| 2022-12-23 | Reiterato | Needham | Buy |
| 2022-12-20 | Iniziato | Truist | Buy |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-01-28 | Iniziato | Goldman | Buy |
| 2021-12-22 | Iniziato | Oppenheimer | Outperform |
| 2021-12-10 | Iniziato | JP Morgan | Overweight |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-03-12 | Iniziato | Wolfe Research | Outperform |
| 2021-02-18 | Iniziato | Barclays | Overweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-29 | Iniziato | Goldman | Neutral |
| 2020-07-10 | Iniziato | Raymond James | Strong Buy |
| 2020-05-05 | Iniziato | Mizuho | Buy |
| 2020-04-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Ripresa | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Reiterato | Morgan Stanley | Overweight |
| 2017-11-22 | Downgrade | Needham | Strong Buy → Buy |
| 2017-11-21 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Iniziato | Morgan Stanley | Overweight |
| 2017-03-08 | Iniziato | Rodman & Renshaw | Buy |
| 2017-02-06 | Aggiornamento | Needham | Buy → Strong Buy |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Reiterato | Needham | Buy |
| 2015-11-10 | Reiterato | FBR Capital | Outperform |
| 2015-11-09 | Reiterato | ROTH Capital | Buy |
| 2015-07-24 | Reiterato | MLV & Co | Buy |
| 2014-12-31 | Reiterato | ROTH Capital | Buy |
| 2014-11-04 | Aggiornamento | MLV & Co | Hold → Buy |
| 2014-04-28 | Reiterato | Needham | Buy |
Mostra tutto
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics to Announce Third Quarter Results on November 4, 2026 - GlobeNewswire Inc.
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Form 4 Cytokinetics Inc: Nancy Wysenski (Director) For: 16 October By Investing.com - Investing.com Canada
195 shares replace a cash retainer for Cytokinetics (CYTK) director Edward M. Kaye. - Stock Titan
A 195-share award brings Harrington's direct Cytokinetics (CYTK) holdings to 22,127 shares. - Stock Titan
Cytokinetics Director Wendell Wierenga Purchases 97 Shares at $63.92 Each - Kalkine Media
Shares replace a cash retainer as Cytokinetics (CYTK) director Henderson receives 352 shares. - Stock Titan
Officer Fady Malik proposes selling 16,386 Cytokinetics (CYTK) shares from option exercises. - Stock Titan
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $113 - Moomoo
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
29 new hires at Cytokinetics received stock awards. Share awards vest over 3 years; options over 4. - Stock Titan
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - www.marketscreener.com
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says - Yahoo Finance
CYTK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
HC Wainwright & Co. reiterates Buy rating on Cytokinetics, $140 price target - TradingView
Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth? - Yahoo Finance
BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating - Yahoo Finance
Canada authorizes a drug for adults whose thickened heart muscle blocks blood flow - Stock Titan
Cytokinetics Announces Health Canada Approval of MYQORZO® - GlobeNewswire
CYTK Initiated Coverage by William Blair -- Rating Set to Outper - GuruFocus
William Blair Initiates Coverage on Cytokinetics With Outperform Rating - Yahoo Finance
William Blair initiates Cytokinetics stock coverage with outperform rating By Investing.com - Investing.com South Africa
William Blair initiates Cytokinetics stock coverage with outperform rating - Investing.com
Here's How Much $1000 Invested In Cytokinetics 15 Years Ago Would Be Worth Today - Benzinga
Cytokinetics, Incorporated (CYTK) Stock forecasts - Yahoo Finance UK
Cytokinetics Sees Myqorzo Launch Strength Carry Into 2027, RBC Says - marketscreener.com
Cytokinetics (NasdaqGS:CYTK) Stock Forecast & Analyst Predictions - Simply Wall Street
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
UBS cuts Cytokinetics stock price target on valuation, keeps Buy - Investing.com
Cytokinetics Insider Sold Shares Worth $471,600, According to a Recent SEC Filing - Yahoo Finance
A $1.42M proposed share sale at Cytokinetics (CYTK) draws on Robert Blum’s stock options. - Stock Titan
Cytokinetics (CYTK), What Is Behind The Fresh Attention? - Yahoo Finance
Cytokinetics (CYTK) Stock Looks Hard To Pin Down Following Strong Heart Drug Updates - Yahoo Finance
Cytokinetics (CYTK) Reports Phase 3 Aficamten Gains In Non Obstructive HCM - Yahoo Finance
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics presents additional aficamten data from trial - Investing.com
Serious heart failure events affected 4.7% taking aficamten, versus 1.2% on placebo. - Stock Titan
Cytokinetics Q2 2026 Earnings Call: Complete Transcript - Benzinga
Cytokinetics EVP Fady Malik sells $214,830 in company stock - Investing.com
Form 4 Cytokinetics Inc For: 11 October By Investing.com - Investing.com Nigeria
CYTK6536068 Bond Yield and Price — FINRA:CYTK6536068 - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo Finance
Cytokinetics Inc (CYTK) EVP Research & Development Fady Malik Se - GuruFocus
Cytokinetics (CYTK): Company Profile, Stock Price, News, Rankings - Fortune
Cytokinetics Falls as Investors Appear to Take Profits Despite Recent Aficamten Progress - Quiver Quantitative
CYTK6536068 Bond Profile: Coupon and Redemption - TradingView
Wells Fargo Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $105 - Moomoo
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics Inc. Advanced Charts | CYTK - Barron's
Cytokinetics Announces Four Presentations at HFSA 2026 Highlighting Aficamten Data in Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics Inc Azioni (CYTK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cytokinetics Inc Azioni (CYTK) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Oct 20 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 20 '26 |
Sale |
64.01 |
3,500 |
224,035 |
153,902 |
| Blum Robert I | President & CEO |
Oct 12 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
286,044 |
| Blum Robert I | President & CEO |
Oct 12 '26 |
Sale |
62.88 |
7,500 |
471,600 |
278,544 |
| ROBERT BLUM | Director |
Oct 12 '26 |
Proposed Sale |
62.91 |
22,500 |
1,415,475 |
0 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 06 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
| Malik Fady Ibraham | EVP Research & Development |
Oct 06 '26 |
Sale |
61.38 |
3,500 |
214,830 |
153,902 |
| Blum Robert I | President & CEO |
Sep 28 '26 |
Sale |
65.46 |
7,500 |
490,950 |
278,544 |
| Blum Robert I | President & CEO |
Sep 28 '26 |
Option Exercise |
10.60 |
7,500 |
79,500 |
286,044 |
| Malik Fady Ibraham | EVP Research & Development |
Sep 22 '26 |
Option Exercise |
7.80 |
3,500 |
27,300 |
157,402 |
2.17%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):